LN-145 TIL Therapy in Cervical Cancer: Phase 2 Results Posted After Trial Termination

원문 링크: WordPress 원문

Iovance Biotherapeutics posted Phase 2 trial results on ClinicalTrials.gov on July 31, 2026, evaluating LN-145 autologous tumor infiltrating lymphocyte therapy in adults with recurrent, metastatic, or persistent cervical carcinoma, reporting an objective response rate of 21.4 percent among 70 efficacy-evaluable participants in the primary monotherapy cohort. The non-randomized multi-cohort design and high mortality across all arms limit definitive efficacy conclusions, though the durable responses observed in a subset of heavily pretreated patients suggest biological activity warranting further investigation.

The results tables for this five-cohort Phase 2 study were first posted to ClinicalTrials.gov on July 31, 2026, representing the initial public disclosure of outcome data for LN-145 in cervical carcinoma.

210 enrolled

across five cohorts

21.4% ORR

Cohort 1 monotherapy

63 deaths

among 74 infused in Cohort 1

English한국어

AI-generated conceptual illustration; not study data.

Five Cohorts Reveal Modest Response Rates in Heavily Pretreated Patients

Design: Phase 2, non-randomized, open-label, five parallel cohorts, terminated Enrolled: 210 adults ≥ 18 with recurrent/metastatic/persistent cervical carcinoma Analysis population: Cohort 1: 70 evaluable; Cohort 2: 37 evaluable; Cohort 3: 25 evaluable Primary endpoint: Cohorts 1–2: ORR per RECIST v1.1; Cohorts 3–5: AE incidence

The trial enrolled 210 participants across five non-randomized cohorts. Cohort 1 included patients who had progressed after at least one prior systemic therapy regimen, Cohort 2 included patients who had progressed after prior PD-1 inhibitor therapy, Cohort 3 evaluated LN-145 in combination with pembrolizumab, Cohort 4 included previously enrolled patients receiving updated follow-up, and Cohort 5 assessed retreatment with a second LN-145 infusion. The intervention consisted of a single infusion of autologous tumor infiltrating lymphocytes manufactured from each patient resected tumor tissue, preceded by a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine and followed by up to six doses of high-dose interleukin-2. In Cohort 1, the objective response rate by investigator assessment per RECIST version 1.1 was 15 responses among 70 efficacy-evaluable participants, yielding a rate of 21.4 percent. In Cohort 2, 5 responses among 37 evaluable participants produced a rate of 13.5 percent. The combination Cohort 3 showed 13 responses among 25 evaluable participants. Median duration of response in Cohort 1 was 6.8 months, and median overall survival was 8.8 months in Cohort 1 and 27.7 months in Cohort 3. Among 74 infused participants in Cohort 1, 63 deaths occurred during the study period, reflecting the advanced disease burden of this heavily pretreated population.

AI-generated conceptual illustration; not study data.

Personalized Cell Therapy Adds Data to a Sparse Evidence Base

Recurrent and metastatic cervical carcinoma carries a poor prognosis, particularly after progression on platinum-based chemotherapy and immune checkpoint inhibitors. Autologous tumor infiltrating lymphocyte therapy represents a personalized immunotherapy approach that harnesses the patient own immune cells expanded ex vivo to target tumor-specific antigens. The posting of these results provides the most comprehensive publicly available dataset for LN-145 in cervical carcinoma to date, spanning multiple treatment lines and combination strategies. The objective response rates observed in Cohorts 1 and 2, while modest in absolute terms, are notable given the heavily pretreated nature of these populations and the absence of effective standard options after PD-1 inhibitor failure. The combination cohort data with pembrolizumab, though from a small US-only sample, suggests a potential synergistic signal that could inform future trial design. For the broader field of adoptive cell therapy, these results contribute to the evolving evidence base for TIL-based approaches across solid tumor types, complementing ongoing investigations in melanoma, non-small cell lung cancer, and other epithelial malignancies. The data also highlight the manufacturing and logistical challenges of personalized cell therapies, where tumor tissue availability, manufacturing turnaround time, and patient fitness for lymphodepleting conditioning all constrain the treatable population.

High Mortality and Open-Label Design Constrain Interpretation

The non-randomized, open-label, multi-cohort design without a concurrent comparator arm precludes causal attribution of observed responses to LN-145. The study was terminated before completing planned enrollment, and the reasons for termination are not fully detailed in the posted results. Different cohorts enrolled patients with different prior treatment histories, making cross-cohort comparisons unreliable. The high mortality observed across all cohorts, with 63 deaths among 74 infused participants in Cohort 1 alone, reflects the advanced disease burden and limited life expectancy of this population rather than a definitive safety signal attributable to the intervention. Objective response was assessed by investigators rather than by independent blinded central review, introducing potential assessment bias. No confidence intervals were reported for the primary endpoint estimates, limiting the precision of the reported response rates. The combination Cohort 3 was restricted to US sites and enrolled only 25 evaluable participants, constraining the generalizability of the combination safety and efficacy data. Adverse event reporting in the posted results includes treatment-emergent events but does not provide granular causality attribution or severity grading for all events. The lymphodepleting conditioning regimen and high-dose interleukin-2 support carry their own substantial toxicity profiles, which are inherent to the TIL therapy platform and not specific to LN-145.

AI-generated conceptual illustration; not study data.

Termination Leaves the Development Pathway Uncertain

The termination of this multi-cohort trial raises questions about the future development pathway for LN-145 in cervical carcinoma. Iovance Biotherapeutics has not announced a successor trial or a modified protocol addressing the enrollment and feasibility challenges encountered in this study. The posted results fulfill a regulatory transparency obligation and provide the research community with a complete dataset for systematic review and meta-analytic purposes. For regulatory agencies, these data alone are insufficient to support a marketing authorization application, and the product remains investigational for cervical carcinoma in all jurisdictions. Future evidence generation is likely to depend on international collaborative registries, expanded access programs, and potentially smaller biomarker-enriched trial designs that target patients most likely to benefit from TIL therapy. The combination strategy with checkpoint inhibitors, suggested by the Cohort 3 data, may warrant dedicated prospective evaluation in a controlled setting. Clinicians managing recurrent cervical carcinoma should continue to follow established treatment guidelines and consider clinical trial enrollment where available. Patients and caregivers should discuss treatment options with their oncology team and should not interpret these registry-posted results as evidence of proven clinical benefit or regulatory endorsement. The field of adoptive cell therapy continues to evolve rapidly, and these results represent one data point in a broader landscape of investigational immunotherapy approaches for gynecologic malignancies.

These results are from a terminated Phase 2 trial registered on ClinicalTrials.gov and do not constitute peer-reviewed published evidence. The non-randomized multi-cohort design and high mortality preclude definitive efficacy or safety conclusions. Registration results are not equivalent to regulatory approval or clinical guideline endorsement. Association between LN-145 and observed responses cannot be established from this uncontrolled, terminated study.

ClinicalTrials.gov NCT03108495 — Full Study Record

This article is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for diagnosis and treatment decisions.